To study the effect of GRP on human prostate cancer xenografts in vivo, immunodeficient NSG mice were subcutaneously injected with PC3 cells and treated with [Tyr4, d-Phe12]-Bombesin when the tumor size reached 10 mm3 (Fig. 6h–j). The gene discussed is GRP; the disease is prostate cancer.